Toxicity and patient-reported quality of life through 12 months following pelvis-inclusive once-weekly stereotactic body radiotherapy versus conventional IMRT for high-risk prostate cancer: updated results of the SRAM randomized phase II trial

Radiotherapy & Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles